Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 36,535 |
|
|||||
| News | - | ||||||
| Day High | 1.26 | Low High |
|||||
| Day Low | 1.22 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AVROBIO Inc | AVRO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.02 | 1.64% | 1.24 | 15:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.23 | 1.22 | 1.26 | 1.24 | 1.22 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 341 | 36,535 | US$ 1.24 | US$ 45,137 | - | 0.57 - 1.70 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:46:46 | 20 | US$ 1.2694 | USD |
AVROBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 56.08M | 44.86M | - | 0 | 12.4M | 0.28 | 4.52 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AVROBIO News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVRO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.26 | 1.29 | 1.20 | 1.25 | 157,550 | -0.02 | -1.59% |
| 1 Month | 1.26 | 1.31 | 1.15 | 1.25 | 167,901 | -0.02 | -1.59% |
| 3 Months | 1.35 | 1.39 | 1.01 | 1.25 | 308,334 | -0.11 | -8.15% |
| 6 Months | 1.55 | 1.61 | 1.01 | 1.33 | 282,734 | -0.31 | -20.00% |
| 1 Year | 0.9301 | 1.70 | 0.57 | 1.29 | 979,205 | 0.3099 | 33.32% |
| 3 Years | 10.32 | 12.005 | 0.56 | 2.08 | 689,878 | -9.08 | -87.98% |
| 5 Years | 20.58 | 29.32 | 0.56 | 5.53 | 542,395 | -19.34 | -93.97% |
AVROBIO Description
| Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease. |
